This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (
www.apricusbio.com ) announced today that it will hold a conference call to discuss its recent corporate highlights on Monday, August 12, 2013 at 9:00 AM ET.
The call can be accessed in the U.S. by dialing (877) 407-8031 and outside of the U.S. by dialing (201) 689-8031 and asking the conference operator for the Apricus Bio Conference Call. The conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=171412 . The teleconference replay will be available for one week by dialing in the U.S. (877) 660-6853 and outside of the U.S. by dialing (201) 612-7415. Replay Passcode 418593 is required for playback. The webcast replay will be available for three months.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros
®, for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus Bio's marketing partners which include, Abbott Canada, Takeda Pharmaceuticals International GmbH, Sandoz, and Bracco SpA. Femprox
®, the Company's product candidate for the treatment of female sexual interest / arousal disorder, has successfully completed a nearly 400-subject proof-of-concept study.
For further information on Apricus Bio, visit
CONTACT: Apricus Bio Investor Relations:
David Pitts or Lourdes Catala